The study and its comparison
PROSPECT randomized 2,653 critically ill adults in forty-four intensive-care units to enteral Lactobacillus rhamnosus GG or placebo. The primary outcome was independently adjudicated ventilator-associated pneumonia. [1]
Pneumonia occurred in about twenty-two percent in each group. None of twenty prespecified secondary outcomes significantly differed. Fifteen probiotic recipients versus one control met the adverse-event definition involving L. rhamnosus at specified body sites. [1]
What the finding establishes
That event definition is more precise than calling every event a bloodstream infection. These results concern critically ill ventilated patients and this strain, rather than the risk in healthy consumers. Authors disclosed research awards and several industry relationships; complete funding was not established from the abstract. The result does not support assuming a familiar probiotic is harmless in intensive care. [1]
A hypothetical distinction
Imagine an intervention fails to prevent infection and adds organism-related events. A microbiome rationale cannot substitute for the measured balance.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Effect of Probiotics on Incident Ventilator-Associated Pneumonia in Critically Ill Patients: A Randomized Clinical Trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.